FDA OKs Cartridge-Based Companion Diagnostic Test for Colorectal Cancer
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
The test provides fully automated, sample-to-result testing to identify patients eligible for immunotherapy treatment.
Proscia and Owkin announced a partnership to integrate AI-driven MSI screening technology, expanding access to colorectal cancer diagnostics.
Universal DX initiated a clinical trial for its colorectal cancer screening blood test with the goal of achieving FDA premarket approval.
The FDA’s Medical Devices Advisory Committee recommended approval of Guardant Health’s Shield blood test for colorectal cancer screening.
Read MoreA new study found that 7.4% of patients repeated fecal testing rather than proceeding directly to colonoscopy as guidelines recommend.
Read MoreOffering a choice between colonoscopy and a take-home screening kit more than doubled colorectal cancer screening rates.
Read MoreMainz Biomed N.V. announced results from a clinical study to evaluating integrating its portfolio into its colorectal cancer screening tool.
Read MoreMainz Biomed will present the findings of a study that evaluated its multimodal screening test for the detection of colorectal cancer.
Read MoreGeneoscopy received U.S. FDA approval for ColoSense, a noninvasive colorectal cancer screening test that uses RNA biomarkers.
Read MoreA significant gap exists in ensuring timely follow-up with colonoscopy after a positive stool test, hindering the effectiveness of screening.
Read MoreNew studies are cautioning against the use of blood tests to replace established colorectal cancer screening tests.
Read MoreResearchers say the test has the best performance for the detection of both colorectal cancer and advanced precancerous polyps.
Read MoreThe blood test is intended for screening colorectal cancer in people who are of average risk and not experiencing symptoms.
Read MoreThe PreveCol test for cancer is aimed at the early detection of biomarkers in blood associated with colorectal neoplasia.
Read MoreGuardant Health announced the FDA is scheduled to review the premarket approval application for the company’s colorectal cancer blood test.
Read MoreResearchers found that about 10% of at-home screening tests for colorectal cancer tests could not be processed, mostly due to patient error.
Read MoreDiaCarta has received US FDA 510(k) clearance for its over the counter (OTC) at home iColon Fecal Occult Blood Test (FOBT).
Read MoreUniversal DX announced a strategic collaboration with Quest Diagnostics designed to improve colorectal cancer screening in the United States.
Read More